Baxter pays $157 million for haemostat company Fusion
This article was originally published in Clinica
Baxter is to expand its biosurgery and tissue repair business by buying Fusion Medical Technologies in a $157 million stock-for-stock merger. Baxter is offering $10 per share, representing a 20% premium on Fusion's share price before the announcement of the deal. It subsequently rose 18% to $9.80.